Detalhe da pesquisa
1.
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Cancer Sci
; 110(5): 1686-1694, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30815927
2.
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Neurooncol Adv
; 6(1): vdae037, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38690230
3.
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Neurooncol Adv
; 5(1): vdad109, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37744697
4.
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.
Int J Hematol
; 117(4): 553-562, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576659
5.
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Neuro Oncol
; 23(1): 122-133, 2021 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32583848
6.
3-O-ß-D-Glucopyranosyltheobroxide from Aerial Parts of Cowpea (Vigna unguiculata).
Nat Prod Commun
; 11(5): 673-6, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27319148